Jennifer A Woyach

List of Publications by Citations

104 papers	5,439 citations	28 h-index	73 g-index
109 ext. papers	6,700 ext. citations	7 avg, IF	5.37 L-index

#	Paper	IF	Citations
104	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *New England Journal of Medicine*, **2014**, 370, 2286-94	59.2	800
103	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 323-32	59.2	621
102	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *New England Journal of Medicine*, **2018**, 379, 2517-2528	59.2	455
101	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. *JAMA Oncology*, **2015**, 1, 80-7	13.4	398
100	The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood*, **2012**, 120, 1175-84	2.2	291
99	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
98	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. *Blood*, **2014**, 123, 1810-7	2.2	218
97	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet, The*, **2020**, 395, 1278-1291	40	201
96	Ibrutinib treatment improves T cell number and function in CLL patients. *Journal of Clinical Investigation*, **2017**, 127, 3052-3064	15.9	197
95	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *American Journal of Hematology*, **2019**, 94, 1353-1363	7.1	152
94	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2015**, 21, 3705-15	12.9	147
93	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). *Blood*, **2014**, 123, 1207-13	2.2	144
92	Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 164-70	5.6	120
91	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. *Journal of Clinical Oncology*, **2011**, 29, 1349-55	2.2	113
90	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. *Blood*, **2015**, 126, 842-50	2.2	111
89	Targeted therapies in CLL: mechanisms of resistance and strategies for management. *Blood*, **2015**, 126, 471-7	2.2	96
88	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 2831-2841	12.9	88

87	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Advances*, **2017**, 1, 1739-1748	7.8	85
86	Hypertension and incident cardiovascular events following ibrutinib initiation. *Blood*, **2019**, 134, 1919-1928	2.2	79
85	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. *Cancer Discovery*, **2018**, 8, 1300-1315	24.4	73
84	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. *Cancer Discovery*, **2018**, 8, 458-477	24.4	67
83	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. *Leukemia*, **2019**, 33, 2527-2530	10.7	51
82	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. *Nature Communications*, **2020**, 11, 4268	17.4	45
81	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. *Blood*, **2014**, 124, 3553-60	2.2	44
80	New therapeutic advances in the management of progressive thyroid cancer. *Endocrine-Related Cancer*, **2009**, 16, 715-31	5.7	39
79	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. *Cancer Discovery*, **2020**, 10, 394-405	24.4	38
78	How I manage ibrutinib-refractory chronic lymphocytic leukemia. *Blood*, **2017**, 129, 1270-1274	2.2	35
77	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 3626-3637	2.2	34
76	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. *Blood*, **2017**, 130, 830-830	2.2	25
75	Targeting BTK through microRNA in chronic lymphocytic leukemia. *Blood*, **2016**, 128, 3101-3112	2.2	25
74	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 7-15	4.7	22
73	Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2016**, 128, 639-639	2.2	21
72	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. *Blood*, **2021**, 137, 3327-3338	2.2	18
71	Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 355-60	3.1	17
70	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. *Circulation*, **2019**, 139, 2594-2596	16.7	16

69	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. *Seminars in Oncology*, **2016**, 43, 300-10	5.9	16
68	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. *Blood*, **2015**, 125, 284-95	2.2	15
67	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.. *Leukemia*, **2022**,	10.7	15
66	The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 3232-3232	2.2	14
65	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. *Cancer Medicine*, **2017**, 6, 778-787	4.8	12
64	Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. *British Journal of Haematology*, **2019**, 185, 363-366	4.5	12
63	E TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. *Clinical Cancer Research*, **2019**, 25, 6260-6273	12.9	11
62	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. *Cell and Bioscience*, **2021**, 11, 197	9.8	10
61	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-10	7.1	10
60	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 9-10	2.2	9
59	Targeting phosphatidylinositol 3 kinase- and - for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. *Blood Advances*, **2020**, 4, 4382-4392	7.8	9
58	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. *Resuscitation*, **2019**, 142, 30-37	4	8
57	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. *British Journal of Haematology*, **2015**, 170, 200-7	4.5	7
56	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). *Blood*, **2019**, 134, 1754-1754	2.2	7
55	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2920-2920	2.2	7
54	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. *Blood*, **2016**, 128, 4387-4387	2.2	7
53	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. *Blood*, **2016**, 128, 55-55	2.2	7
52	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 691-4	7.1	7

51	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. *Clinics in Geriatric Medicine*, **2016**, 32, 175-89	3.8	6
50	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. *British Journal of Haematology*, **2019**, 187, 399-402	4.5	6
49	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. *Blood*, **2016**, 128, 3238-3238	2.2	5
48	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. *Therapeutic Advances in Hematology*, **2020**, 11, 2040620720912990	5.7	5
47	REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK. *Blood*, **2016**, 128, 4399-4399	2.2	4
46	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. *Leukemia and Lymphoma*, **2019**, 60, 2308-2311	1.9	4
45	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. *Journal of Hematology and Oncology*, **2021**, 14, 17	22.4	4
44	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. *Blood*, **2020**, 136, 32-33	2.2	3
43	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. *Blood*, **2015**, 126, 2940-2940	2.2	3
42	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. *Blood*, **2016**, 128, 1259-1259	2.2	3
41	The Eμ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. *Blood*, **2015**, 126, 2752-2752	2.2	3
40	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2020**, 26, 6187-6195	12.9	3
39	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. *Journal of Hematology and Oncology*, **2021**, 14, 36	22.4	3
38	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 3049-3049	2.2	2
37	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 2953-2953	2.2	2
36	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. *Blood*, **2016**, 128, 4386-4386	2.2	2
35	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. *Blood*, **2016**, 128, 4388-4388	2.2	2
34	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. *Blood*, **2021**, 138, 392-392	2.2	2

33	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 766-774	2	2
32	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 476-481	3.1	2
31	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. *Leukemia*, **2021**, 35, 2854-2861	10.7	2
30	Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. *Leukemia and Lymphoma*, **2018**, 59, 1461-1465	1.9	1
29	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 22-23	2.2	1
28	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. *Blood*, **2019**, 134, 3045-3045	2.2	1
27	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. *Blood*, **2020**, 136, 2-3	2.2	1
26	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. *Blood*, **2010**, 116, 2456-2456	2.2	1
25	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1232-1232	2.2	1
24	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. *Blood*, **2016**, 128, 2040-2040	2.2	1
23	Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. *Blood*, **2016**, 128, 2705-2705	2.2	1
22	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. *Blood*, **2016**, 128, 4385-4385	2.2	1
21	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.. *Cancer Research Communications*, **2021**, 1, 79-89		1
20	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. *Blood*, **2021**, 138, 2642-2642	2.2	1
19	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. *Blood*, **2016**, 128, 352-352	2.2	1
18	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Leukemia and Lymphoma*, **2021**, 62, 3278-3282	1.9	1
17	A CAPTIVATE-ing new regimen for CLL. *Blood*, **2022**, 139, 3229-3230	2.2	1
16	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. *Nature Communications*, **2021**, 12, 6338	17.4	0

15	Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax. *Blood*, **2021**, 138, 679-679	2.2	0
14	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 2526-2526	2.2	0
13	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 2077-2077	2.2	0
12	Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies. *Blood*, **2015**, 126, 317-317	2.2	0
11	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. *NAR Genomics and Bioinformatics*, **2020**, 2, lqaa070	3.7	0
10	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2021**, 62, 716-721	1.9	0
9	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. *Blood*, **2020**, 136, 29-30	2.2	
8	Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. *Blood*, **2021**, 138, 2252-2252	2.2	
7	LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia. *Blood*, **2019**, 134, 3377-3377	2.2	
6	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies. *Blood*, **2015**, 126, 318-318	2.2	
5	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. *Blood*, **2016**, 128, 3198-3198	2.2	
4	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. *Blood*, **2013**, 122, 2872-2872	2.2	
3	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. *Blood*, **2013**, 122, 2523-2523	2.2	
2	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. *Leukemia*, **2021**, 35, 3287-3290	10.7	
1	Genomics of Resistance to Targeted Therapies. *Hematology/Oncology Clinics of North America*, **2021**, 35, 715-724	3.1	